Clinical Study
Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma
Table 1
Baseline patient characteristics.
| Characteristics | Patients () | Percent |
No. | (%)
|
| Age, years | | | Median
|
60 | | Range | 27–75
| | Sex
| | | Male | 2
|
8 | Female
|
22 | 92
| SWOG performance status | | | 0
|
1 | 4
| 1 | 18
|
75 | 2
|
5 | 20
| Histology | | | Leiomyosarcoma
|
24 | 100
| Primary site | | | Uterus
|
11 | 46
| Retroperitoneum | 3
|
13 | Other
|
10 | 42
| Sites of metastases | | | Lung
|
15 | 63
| Liver | 14
|
58 | Other
|
8 | 33
| Prior treatment | | | Surgery
|
14 | 58
| Radiotherapy | 3
|
13 | Chemotherapy
|
20 | 83
| Doxorubicin | 15
|
67 | Dacarbazine
|
4 | 17
| No. of prior chemo regimens | | | 0
|
4 | 17
| 1 | 6
|
25 | 2
|
9 | 38
| 3 | 5
|
21 |
|
|